Sabrina K.
- Country
- Germany
- Department
- CCC Mainfranken, Interdisziplinäres Studienzentrum mit ECTU
Research Overview
- Phase 1 Evaluation of Allo-RevCAR01-T-CD123 in CD123 Positive Hematologic Malignancies, Including Acute Myeloid Leukemia (AML)
- MRD-Guided Pembrolizumab and Azacitidine Therapy in NPM1-Mutated Acute Myeloid Leukemia with Imminent Hematological Relapse
- Phase 3 Randomized Open-Label Study of Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Steroid-Refractory Acute Graft-Versus-Host Disease
Data & Insights
Has run more than one trial at 36 of 92 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating acute myeloid leukemia (AML), with particular focus on patients with NPM1 mutations. Their research explores innovative combination therapies including immunotherapy approaches.
- Molecular Relapse Management
- Immunotherapy Integration
- Targeted AML Treatment
Additional expertise includes novel therapeutic approaches for CD123-positive hematologic malignancies.
Multiple Myeloma
The investigator focuses on advanced treatment strategies for multiple myeloma, particularly in relapsed and progressive cases following first-line therapy.
- Stem Cell Transplantation
- Salvage Therapy Protocols
- Long-term Survival Outcomes
Expertise includes comparative analysis of allogeneic stem cell transplantation versus conventional therapeutic approaches.
Graft-versus-Host Disease
The investigator specializes in treating complex cases of acute Graft-versus-Host Disease (aGVHD), particularly focusing on steroid-refractory cases and gastrointestinal involvement.
- Novel Cell Therapies
- Microbiome-based Treatments
- Steroid-refractory Disease Management
Research includes innovative approaches using mesenchymal stromal cells and advanced therapeutic solutions for treatment-resistant cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.